Fig. 1.

EmiR expression is associated with clinical stage, cancer subtype, and clinical response to neoadjuvant treatment. Expression of EmiR-21 (a) and EmiR-105 (b) compared between healthy donors (HD), non-metastatic (LBC), and metastatic (MBC) breast cancer patients. EmiR-222 (c) expression according to Perou’s classification in the LBC cohort, divided into four groups: basal-like (BL), luminal A (LA), luminal B (LB), and HER2. EmiR-21 (d) expression at Ext2 in patients with complete response (CR), partial response (PR), or stable disease (SD). Data are presented as a box and whiskers plot (min to max). *p > 0.05 and **p < 0.01. No significant comparisons are not represented